OCGN — Ocugen, Inc. stock price, charts and financials

Latest market price

1.25

+0.02+1.63%

Overview Short InterestFilings

OCGNQT31Ocugen, Inc.·NASDAQ

Overview Short InterestFilings

1.25+1.63%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.22	Insider Own	8.31%	Shs Outstand	338.52M	Perf Week	1.65%

Market Cap	416.38M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.07%	Shs Float	316.84M	Perf Month	-16.89%

Enterprise Value	417.82M	PEG	0.28	EPS next Q	-	Inst Own	-	Short Float	31.75%	Perf Quarter	-28.90%

Income	-75.74M	P/S	93.25	EPS this Y	-2.60%	Inst Trans	-	Short Ratio	12.90	Perf Half Y	-19.08%

Sales	4.46M	P/B	67.89	EPS next Y	-7.22%	ROA	-125.95%	Short Interest	100.59M	Perf YTD	-8.89%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-127987.50%	52W High	2.77 -54.95%	Perf Year	14.95%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-157.55%	52W Low	0.95 32.12%	Perf 3Y	114.29%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	25.99% -	Gross Margin	-	Volatility	6.02% 5.29%	Perf 5Y	-82.28%

Dividend TTM	-	EV/Sales	93.58	EPS Y/Y TTM	-10.00%	Oper. Margin	-1483.85%	ATR (14)	0.08	Perf 10Y	-98.92%

Dividend Ex-Date	-	Quick Ratio	1.86	Sales Y/Y TTM	25.00%	Profit Margin	-1605.22%	RSI (14)	39.91	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	1.86	EPS Q/Q	-20.00%	SMA20	-8.92%	Beta	2.15	Target Price	5.00

Payout	0.00%	Debt/Eq	5.74	Sales Q/Q	100.00%	SMA50	-8.67%	Rel Volume	0.54	Prev Close	1.23

Employees	116	LT Debt/Eq	-2.58	Earnings	Aug 06	SMA200	-19.37%	Avg Volume	7.54M	Price	1.25

IPO Date	Dec 03, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	2.78% 266.89%	Net Debt/EBITDA	-0.02	Volume	4,075,688	Change	1.63%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Mar-01-23	Upgrade	Chardan Capital	Neutral → Buy
Aug-23-22	Initiated	Mizuho	Buy
Aug-15-22	Reiterated	HC Wainwright & Co.	Buy
Jun-18-22	Reiterated	Cantor Fitzgerald	Neutral	$4.50
May-08-22	Reiterated	Chardan Capital	Neutral	$3.50
Apr-25-22	Reiterated	Roth Capital	Neutral
Jun-11-21	Downgrade	Roth Capital	Buy → Neutral
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital	Buy → Neutral
Feb-04-21	Upgrade	HC Wainwright & Co.	Neutral → Buy

Latest News

Jul-31-26

Jul-31-2607:02AM

Ocugen to Participate in Upcoming August Investor Conferencesglobenewswire.com

Jul-29-26

Jul-29-2607:13AM

FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular DegenerationBenzinga

07:01AM

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degenerationglobenewswire.com

Jul-28-26

Jul-28-2604:01PM

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Resultsglobenewswire.com

Jul-13-26

Jul-13-2607:16AM

Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North AfricaBenzinga

07:02AM

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africaglobenewswire.com

Jul-10-26

Jul-10-2608:02PM

Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advancesmarketbeat.com

Jul-01-26

Jul-01-2607:00AM

Ocugen to Participate in Upcoming July Industry Conferencesglobenewswire.com

Jun-25-26

Jun-25-2612:35AM

Ocugen: Financing Risk Is Lower, But The Clinical Bet Still Has To WorkSeekingAlpha

Company

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	5	4	4	6	2	0	0	0	0
Cost of Goods Sold Incl. D&A	0	2	2	1	0	0	6	8	0
Gross Profit	5	2	2	5	2	0	-6	-8	0
Selling, General and Administrative Excl. Other	27	28	27	32	35	23	8	6	10
Research and Development	37	40	32	40	56	35	13	8	16
Other Operating Expense	1	-3	-2	-1	1	0	-6	-8	0
Operating Income	-61	-63	-55	-66	-89	-58	-21	-14	-30
Interest Expense	3	5	0	0	0	0	1	2	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-1	0	1	2	2	0	0	-4	22
Net Income Before Taxes	-64	-68	-54	-63	-87	-58	-22	-20	-9
Income Taxes	0	0	0	0	0	0	0	0	-16
Consolidated Net Income	-64	-68	-54	-63	-87	-58	-22	-20	-9
Net Income From Continuing Operations	-64	-68	-54	-63	-87	-58	-22	-20	-18
Net Income	-64	-68	-54	-63	-87	-58	-22	-20	-9
EPS (Recurring)	-0.22	-0.23	-0.20	-0.26	-0.40	-0.30	-0.31	-1.53	-13.98
EPS (Basic, Before Extraordinaries)	-0.22	-0.23	-0.20	-0.26	-0.40	-0.30	-0.31	-1.53	-13.98
EPS (Diluted)	-0.22	-0.23	-0.20	-0.26	-0.40	-0.30	-0.31	-1.53	-13.98
EBITDA	-58	-60	-52	-62	-86	-58	-14	-14	-14
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	76.00	101.25	54.54	23.38	139.75	—	—	—	—
Gross Margin	100.00	50.00	50.00	83.33	100.00	—	—	—	—
Operating Margin	-1,220.00	-1,575.00	-1,375.00	-1,100.00	-4,450.00	—	—	—	—
Net Margin	-1,280.00	-1,700.00	-1,350.00	-1,050.00	-4,350.00	—	—	—	—
Shares Outstanding	304	300	271	244	215	195	112	14	1
Market Capitalization	380	405	218	140	280	887	205	7	5
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnson-Greene Treerita Essalima	Chief Financial Officer	Jun 15 '26	Buy	1.23	21,000	25,830	521,000	Jun 17
Zhang Junge	Director	Apr 01 '26	Option Exercise	0.79	194,134	154,303	1,359,316	Apr 02
Fernandes Prabhavathi	Director	Nov 26 '24	Buy	0.91	10,000	9,095	10,000	Dec 02
Castillo Kirsten	Director	Nov 22 '24	Buy	0.91	25,000	22,848	75,000	Nov 26
Zhang Junge	Director	Jun 14 '23	Buy	0.50	200,278	99,999	1,077,182	Jun 16
Musunuri Shankar	Chief Executive Officer	Feb 16 '23	Option Exercise	0.33	100,000	33,000	2,290,073	Feb 17
Musunuri Shankar	Chief Executive Officer	Feb 16 '23	Sale	1.08	100,000	108,000	2,190,073	Feb 17
Musunuri Shankar	Chief Executive Officer	Jan 17 '23	Option Exercise	0.51	100,000	51,000	2,327,950	Jan 19
Musunuri Shankar	Chief Executive Officer	Jan 17 '23	Sale	1.28	100,000	128,000	2,227,950	Jan 19
Musunuri Shankar	Chief Executive Officer	Dec 16 '22	Option Exercise	0.51	95,809	48,863	848,349	Dec 20
Musunuri Shankar	Chief Executive Officer	Dec 16 '22	Sale	1.43	95,809	137,007	752,540	Dec 20
Musunuri Shankar	Chief Executive Officer	Oct 14 '22	Option Exercise	0.51	100,000	51,000	852,540	Oct 14
Musunuri Shankar	Chief Executive Officer	Oct 14 '22	Sale	1.66	100,000	166,000	752,540	Oct 14
Kumar Ramesh	Director	Oct 06 '22	Option Exercise	0.51	4,500	2,295	4,500	Oct 07
Kumar Ramesh	Director	Oct 06 '22	Sale	1.83	4,500	8,235	0	Oct 07

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.